Skip to content
Interagency Autism Coordinating Committee (IACC)
Autism Research Database
Office of Autism Research Coordination (OARC)
 
Project Element Element Description

Project Title

Project Title

Investigation of Transgenerational Neurodevelopmental Impacts of Gestational Pharmaceuticals

Principal Investigator

Principal Investigator

Mortensen, Erik

Description

Description

Prenatal pharmaceutical use was widespread from the 1950s through the early 1970s, based partly on the belief that medications could protect pregnancies deemed at-risk while posing no risk to the fetus. The drugs used, including progestins, estrogens, corticosteroids, barbiturates, morning sickness medications, and many other drugs used to treat a variety of conditions, were often administered from the very beginning of pregnancy, and millions of women around the world were treated with them. Many of these drugs are no longer in use, but prenatal pharmaceutical use continues to be widespread today, in spite of the lack of examination of potential effects on the descendants of children exposed to prenatal chemicals. This study will be the first to examine potential developmental abnormalities in humans, specifically in the grandchildren of Danish women given prenatal pharmaceuticals in the period from 1969-71. The study will use existing registers to ascertain abnormal outcomes in the offspring of the exposed individuals (those who were embryos and fetuses at the time of the exposures, but who are now 41-43 years old), and also directly contact them with a questionnaire about the development of their offspring. These studies will look for an array of neurological consequences, transmitted from generation to generation, and will greatly inform our understanding of the development of simple learning disabilities to the most severe of autism spectrum disorders.

Funder

Funder

Autism Speaks

Fiscal Year Funding

Fiscal Year Funding

100000

Current Award Period

Current Award Period

2013-2014

Strategic Plan Question

Strategic Plan Question

Question 3: What Caused This To Happen And Can This Be Prevented?

Strategic Plan Objective

Strategic Plan Objective

Green dot: Objective has greater than or equal to the recommended funding. 3SH. Support at least three studies of special populations or use existing databases to inform our understanding of environmental risk factors for ASD in pregnancy and the early postnatal period by 2012. Such studies could include: o Comparisons of populations differing in geography, gender, ethnic background, exposure history (e.g., prematurity, maternal infection, nutritional deficiencies, toxins), and migration patterns; and o Comparisons of phenotype (e.g., cytokine profiles), in children with and without a history of autistic regression, adverse events following immunization (such as fever and seizures), and mitochondrial impairment. These studies may also include comparisons of phenotype between children with regressive ASD and their siblings. Emphasis on environmental factors that influence prenatal and early postnatal development is particularly of high priority. Epidemiological studies should pay special attention to include racially and ethnically diverse populations. IACC Recommended Budget: $12,000,000 over 5 years.

Project Link

Project Link

Investigation of Transgenerational Neurodevelopmental Impacts of Gestational Pharmaceuticals (External web link)

Institution

Institution

Institute of Preventive Medicine at Frederiksberg Hospital

State/Country

State/Country

Denmark

Project Number

Project Number

8428

Federal or Private?

Federal or Private?

Private

Received ARRA Funding?

Received ARRA Funding?

No

History/Related Projects

History/Related Projects

Investigation of Transgenerational Neurodevelopmental Impacts of Gestational Pharmaceuticals | 0 | 2014 | 8428
Investigation of Transgenerational Neurodevelopmental Impacts of Gestational Pharmaceuticals | 0 | 2015 | 8428

 
Back to Top